Compare CFR & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFR | BIO |
|---|---|---|
| Founded | 1868 | 1952 |
| Country | United States | United States |
| Employees | 6008 | 7450 |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.1B |
| IPO Year | N/A | N/A |
| Metric | CFR | BIO |
|---|---|---|
| Price | $131.16 | $265.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | $143.08 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 517.9K | 237.8K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.72 | $2.74 |
| Revenue Next Year | $4.70 | $3.05 |
| P/E Ratio | $14.55 | ★ $9.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $100.31 | $211.43 |
| 52 Week High | $148.97 | $343.12 |
| Indicator | CFR | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 32.55 | 41.30 |
| Support Level | $124.76 | $239.33 |
| Resistance Level | $132.83 | $289.61 |
| Average True Range (ATR) | 3.29 | 7.68 |
| MACD | -0.91 | 0.48 |
| Stochastic Oscillator | 15.73 | 24.82 |
Cullen/Frost is a regional US bank with around $53 billion in assets (as of December 2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.